This visionary leap is encapsulated in the concept of “AI Dermatology 2.0,” which revolutionizes diagnostic thinking by moving beyond mere pattern recognition—the cornerstone of conventional AI—toward a model that actively seeks to understand the “why” behind observed skin abnormalities. While Correlative AI (1.0) identifies symptoms and categorizes diseases based on visual and data patterns, AI 2.0 employs causal inference algorithms to decipher the underlying mechanisms and pathways responsible for dermatological disorders, fundamentally enriching diagnostic accuracy and therapeutic strategy development.

The technical ingenuity of causal AI lies in its ability to simulate complex biological interactions within the skin’s microenvironment, facilitating precise identification of rare and elusive skin diseases. Empirical studies demonstrate that these causal algorithms can enhance diagnostic accuracy by up to 32.9% over previous models. This is particularly critical in cases where subtle clinical signs or overlapping symptomatology confound traditional diagnostic approaches, fostering earlier and more reliable detection, which is essential for mitigating disease progression.

Central to the capabilities of AI Dermatology 2.0 are “skin digital twins”—high-fidelity virtual replicas of individual patients’ skin created using integrative data from genomics, proteomics, imaging, and clinical history. These digital constructs allow researchers and clinicians to conduct virtual drug trials in silico, bypassing many ethical and logistical constraints of traditional clinical trials. Moreover, the technology enables precise forecasting of disease flare-ups, notably predicting eczema exacerbations within a 72-hour window with over 90% accuracy, empowering proactive intervention strategies.

Beyond diagnostics and forecasting, AI 2.0 functions as an intelligent collaborator within the healthcare ecosystem. By augmenting the diagnostic processes at the primary care level, it enhances clinical decision-making, raising diagnostic accuracy from approximately 73% to 82%. This elevation not only improves patient outcomes but also alleviates the workload on specialized dermatology services. For chronic diseases such as hidradenitis suppurativa, often suffering from decade-long diagnosis delays, the integration of causal AI represents a pathway to significantly shorten diagnosis times and initiate timely treatment.

A critical paradigm shift inherent in AI 2.0 is its role in redefining dermatologists’ responsibilities. Rather than rendering specialists obsolete, the technology is designed to empower them to become “system commanders,” overseeing complex cases that require nuanced clinical judgment and individualized patient care. This orchestration underscores a future clinical model where human expertise and autonomous AI operate synergistically, optimizing healthcare delivery and fostering precision medicine.

The theoretical underpinning of AI 2.0 is grounded in advanced methods of causal inference, which mathematically model cause-effect relationships rather than mere associations. This enables a shift from reactive healthcare towards proactive risk interception, focusing on sustaining lifelong skin homeostasis. Such an approach promises to transform dermatological care from episodic treatment of symptoms to continuous management of underlying risks, thereby improving long-term patient well-being.

From a technical standpoint, integrating AI 2.0 into clinical workflows entails a multidisciplinary fusion of data science, dermatology, computational biology, and systems medicine. Real-world implementation leverages large datasets curated from diverse populations, enhancing algorithm robustness and generalizability. Continuous learning frameworks within AI permit adaptation to emerging data trends, diseases, and therapeutic modalities, ensuring the system evolves in tandem with scientific advancements.

Challenges remain in ensuring equitable access to this transformative technology, particularly in resource-limited settings where dermatological expertise is most scarce. Addressing biases inherent in training datasets, guaranteeing patient privacy, and aligning regulatory frameworks will be essential to facilitate the responsible and widespread adoption of AI 2.0 in dermatology. Multistakeholder collaboration will be indispensable to surmount these hurdles and to harness AI’s full potential in improving global skin health.

In summary, “Dermatology AI 2.0” represents a seismic shift in the approach to diagnosing and managing skin diseases by embedding causal reasoning and autonomous intelligence into clinical and research paradigms. This approach markedly elevates diagnostic precision, enables personalized virtual trials, and empowers clinicians to foresee and intercept disease progression. As dermatology embraces the era of causal AI, the promise of achieving lifelong skin homeostasis across diverse patient populations comes ever closer to realization.

Published in the journal Skin on May 11, 2026, this seminal work—titled “Dermatology AI 2.0: A Paradigm Shift Towards Causal Inference, Precision Forecasting, and Autonomous Intelligence”—sets the stage for the next generation of dermatological AI technologies. Authored by Prof. Yang Yang and collaborators, the review outlines the theoretical foundations, experimental validations, and prospective clinical applications of this transformative AI framework. The research embodies a critical milestone in marrying AI innovation with dermatological practice, heralding a future where intelligent systems profoundly augment healthcare delivery and patient outcomes.

Subject of Research: Not applicable
Article Title: Dermatology AI 2.0: A Paradigm Shift Towards Causal Inference, Precision Forecasting, and Autonomous Intelligence
News Publication Date: 11-May-2026
Web References: http://dx.doi.org/10.2738/SKIN.2026.0004
Image Credits: HIGHER EDUCATION PRESS
Keywords: Skin diseases, AI Dermatology 2.0, Causal inference, Precision forecasting, Autonomous intelligence, Skin digital twins, Rare skin disease diagnosis, Virtual drug trials, Eczema flare prediction, Diagnostic accuracy, Hidradenitis suppurativa, Lifelong skin homeostasis

The study, conducted by a team of researchers led by Dachawar, Sampathi, and Ladkat, emphasizes the necessity of early and accurate detection of baldness. Androgenetic alopecia, often referred to as male or female pattern baldness, is a prevalent condition that affects a substantial portion of the population. The emotional toll and social implications of hair loss can be significant, leading to a demand for effective management strategies. With technological advancements, researchers have aimed to create AI-driven solutions that provide not only diagnosis but also personalized treatment recommendations for individuals.

One of the highlights of this research is the utilization of image processing techniques combined with deep learning algorithms. The study harnesses the power of convolutional neural networks (CNNs) to analyze thousands of images of scalp conditions. By generating a robust dataset, the AI models can learn to differentiate between varying stages and types of baldness, thus enhancing the accuracy of diagnosis. This automated process not only saves time but also reduces the risk of human error in assessments traditionally performed by dermatologists.

Moreover, the research delves into the classification of baldness patterns using AI algorithms. Through the deployment of advanced machine learning techniques, the team has developed models capable of identifying distinct hair loss patterns. These models can accurately predict the likelihood of progression based on initial assessment, allowing healthcare providers to tailor treatment plans to individual patients. By moving beyond one-size-fits-all approaches, this personalized medicine framework increases the chances of successful intervention and possibly regrowing hair.

In exploring treatment options, the researchers incorporated AI for recommending various therapeutic modalities based on the individual’s unique profile. Whether it involves topical treatments, pharmaceuticals, or even surgical options like hair transplants, AI can guide clinicians in selecting the most appropriate course of action. This guidance is grounded in not just current best practices but also the latest research findings, pushing the boundaries of conventional treatment paradigms.

The integration of telemedicine is another significant aspect of this innovative approach. As patients seek convenience and accessibility, telehealth platforms equipped with AI capabilities offer real-time consultations regarding hair loss concerns. Patients can upload images for analysis, receiving immediate feedback on the condition of their scalp. This eliminates geographical barriers, allowing individuals in remote locations to access expert advice without the need for extensive travel.

Importantly, there is an emphasis on ethical considerations associated with AI in healthcare. The researchers underline the significance of patient data privacy and the essential need for informed consent in the application of AI technologies. By transparently communicating how patient data will be used, researchers can foster trust and encourage wider acceptance of AI-driven solutions in medical practice.

Moreover, the study reflects on the ongoing dialogue regarding biases in AI datasets. To ensure that AI models are generalizable and effective across diverse populations, researchers need to be conscientious about the demographics represented in their training sets. Inclusive practices will help eliminate disparities in care and guarantee that individuals from varied backgrounds benefit equally from technological advancements.

As the dialogue around baldness detection continues to evolve, this research does not merely represent a scientific achievement but also inspires hope for those experiencing hair loss. Acknowledging that while AI may not reverse baldness for everyone, it signifies a leap towards more effective management solutions. The potential of personalized treatments aligned with real-world data captured through AI applications opens new pathways for recovery and reintegration into society for affected individuals.

The implications of this work expand beyond dermatology. By demonstrating the effective use of AI in diagnosing and managing a specific health condition, it serves as a blueprint for future applications across different medical fields. From cardiovascular health to diabetes management, integrating AI technologies can spark similar revolutions, enhancing patient outcomes globally.

In conclusion, the pioneering research into baldness detection and management signifies a transformative shift in how we approach common health issues through technology. The implementation of artificial intelligence and machine learning not only enhances diagnostic accuracy but also personalizes treatment methodologies. As society continue to embrace the possibilities presented by AI, the future of healthcare indeed looks promising, with the potential to change countless lives for the better.

Subject of Research: Baldness Detection and Management with AI

Article Title: Innovative approaches to baldness detection and management with artificial intelligence and machine learning

Article References:

Dachawar, M., Sampathi, S., Ladkat, V.V. et al. Innovative approaches to baldness detection and management with artificial intelligence and machine learning.
Arch Dermatol Res 318, 36 (2026). https://doi.org/10.1007/s00403-025-04477-4

Image Credits: AI Generated

DOI: 03 January 2026

Keywords: Baldness detection, AI, machine learning, dermatology, hair loss management, telemedicine, personalized treatment, ethical considerations, healthcare technology.

Melanoma, one of the deadliest forms of skin cancer, often remains undetected until it reaches advanced stages where treatment becomes significantly more challenging. Early identification is foundational to improving patient prognosis and survival rates. As the prevalence of skin cancers rises globally, the necessity for efficient diagnostic solutions has never been more urgent. Traditional diagnostic methods heavily rely on the expertise of dermatologists, which can sometimes yield inconsistent results due to subjective interpretations. Thus, the integration of artificial intelligence into this field marks a transformative evolution.

The study leverages dermoscopy images, which are critical in the evaluation of skin lesions. These images provide intricate insights into skin features that are crucial for distinguishing between benign and malignant growths. However, manually analyzing dermoscopy images can be tedious and prone to error, underscoring the need for automated systems that can deliver accurate assessments.

By implementing a hybrid model that amalgamates the strengths of both CNNs and ANNs, the research team addressed the limitations often encountered in stand-alone systems. CNNs excel at extracting high-level features from images, leveraging deep learning architectures to recognize patterns that are not readily visible to the human eye. In contrast, ANNs contribute robust decision-making capabilities that utilize these features to enhance classification performance. The synergistic effect of combining these methodologies results in a powerful tool capable of discerning melanoma with improved precision.

This multifaceted approach begins at the preprocessing stage, where dermoscopy images are meticulously adjusted to ensure uniformity, thus optimizing the input for machine learning algorithms. Subsequent layers of CNN are designed to capture rich and complex features of skin lesions, progressively refining the image data to extract essential characteristics. The outputs from these convolutional layers are then funneled into the ANN, where sophisticated algorithms analyze the extracted features, culminating in a decisive classification of the images as benign or malignant.

In their experiments, the researchers utilized a comprehensive dataset comprising diverse dermoscopy images, ranging from common benign moles to various stages of melanoma. This diversity is crucial as it ensures that the model generalizes well across different skin types and conditions, a common challenge in dermatological diagnostics. The evaluation metrics used in the study reaffirmed the model’s effectiveness, showcasing notable improvements in accuracy, sensitivity, and specificity metrics over existing models.

Moreover, the study underscores the importance of explainability in AI-driven medical solutions. As healthcare professionals increasingly adopt AI tools, it becomes essential that these systems not only produce accurate results but also provide clear reasoning for their classifications. The architecture of the model designed in this study was enhanced to provide visual feedback on the decision-making process, allowing dermatologists to interpret AI findings more effectively and integrate them seamlessly into their clinical practices.

This research adds a significant layer of utility by presenting a robust framework that could potentially be integrated into current clinical systems, paving the way for real-time melanoma detection solutions in dermatology offices and hospitals across the globe. As AI technology evolves, its contributions to healthcare are destined to grow, transforming how medical professionals approach diagnostics and patient care.

The researchers have called for collaboration between technologists and healthcare practitioners to consistently refine these models further, making them even more tailored to specific populations. Cultural and geographical differences can influence the presentation of skin lesions, and thus the training datasets should reflect this diversity for broader applicability.

Additionally, the study opens doors for future explorations into integrating other forms of imaging technologies or data points, such as genetic markers, which could further enhance predictive capabilities. The potential for these AI-driven models to incorporate vast amounts of patient data creates a fertile ground for pioneering research that promises to redefine cancer care methodologies.

As this innovative modality permeates the medical landscape, it also brings important discussions about ethical considerations surrounding the deployment of AI in healthcare. Issues such as data privacy, algorithmic bias, and the need for regulatory frameworks are essential conversations as the technology matures. Ensuring that these systems function equitably and responsibly within society is paramount as we navigate the future of AI and medicine.

The team of Alshmrani, Alotaibi, and Alfakeeh is poised at the forefront of this transformative field, championing a model that not only enhances clinical accuracy but also bridges the gap between AI capabilities and practical applications in medicine. Their contributions underscore an exciting future in which technology and healthcare converge to enhance patient outcomes with unprecedented precision and reliability.

In conclusion, the fusion of multi CNN features with ANN represents an important advancement in the early classification of melanoma using dermoscopy images. By integrating cutting-edge machine learning techniques with rigorous medical analysis, this study not only showcases the potential of artificial intelligence but also highlights a pathway for improved diagnostic practices in dermatology, ultimately aiming to enhance patient care and outcomes in oncology.

Subject of Research: Early classification of melanoma using dermoscopy images through a hybrid model of CNN and ANN

Article Title: Fusion of multi CNN features with ANN for early classification of melanoma using dermoscopy images

Article References:

Alshmrani, A.S., Alotaibi, F.M. & Alfakeeh, A.S. Fusion of multi CNN features with ANN for early classification of melanoma using dermoscopy images.
Discov Sustain (2026). https://doi.org/10.1007/s43621-025-02556-0

Image Credits: AI Generated

DOI: 10.1007/s43621-025-02556-0

Keywords: melanoma, early classification, dermoscopy images, convolutional neural networks, artificial neural networks, machine learning, healthcare innovation, medical imaging, AI in dermatology, skin cancer detection.

Cutaneous squamous cell carcinoma ranks as the second most common skin malignancy in Sweden, trailing only basal cell carcinoma. Its incidence is rising sharply, with over 10,000 new cases diagnosed annually across the country. cSCC primarily affects sun-exposed anatomical regions such as the face and neck, where cumulative ultraviolet (UV) radiation inflicts molecular damage over many years, initiating oncogenic mutations in keratinocytes—the predominant cell type in the epidermis.

Dr. Sam Polesie, an associate professor specializing in dermatology and venereology at the University of Gothenburg, led the research team that spearheaded the AI model’s development. “The pathogenesis of squamous cell carcinoma is intimately linked to chronic UV exposure, which induces mutagenic alterations in skin cells. Clinically, these tumors often present on sun-damaged skin characterized by irregular pigmentation, thickened, ulcerated lesions, and compromised elasticity,” explains Polesie. Despite the relative ease of recognizing the disease itself, stratifying tumors according to their biological aggressiveness remains a formidable clinical challenge.

Current medical protocols in Sweden and many other countries generally forgo preoperative punch biopsies in suspected cSCC cases. Instead, patients undergo surgery based solely on clinical suspicion, and the excised tissue undergoes subsequent histopathological examination to confirm diagnosis and guide follow-up care. However, without a biopsy guiding initial treatment, clinicians face significant uncertainty regarding the tumor’s growth potential, complicating surgical planning. Aggressive tumors necessitate prompt, extensive surgical excision with wider margins to minimize recurrence risk, whereas less aggressive lesions may be addressed using more conservative approaches.

Acknowledging these diagnostic hurdles, the research team focused on leveraging machine learning to analyze a robust dataset comprising 1,829 close-up clinical images of pathologically confirmed squamous cell carcinomas. The AI was trained to categorize tumors into three distinct tiers of aggressiveness based on morphological features extracted through advanced image processing algorithms. Subsequent validation utilized an independent test set of 300 images, comparing the AI’s predictive accuracy directly against evaluations performed by a cohort of seven experienced dermatologists.

The study, published in the Journal of the American Academy of Dermatology, revealed that the AI model’s performance in differentiating tumor aggressiveness was statistically indistinguishable from that of the expert clinicians. Intriguingly, the interobserver variability among dermatologists themselves was only moderate, highlighting inherent subjectivity and complexity in human assessments. These findings illustrate that AI can standardize and potentially enhance diagnostic reliability in preoperative settings, offering consistent and swift decision support.

Among the salient clinical indicators identified as correlating strongly with aggressive tumor phenotypes were the presence of ulcerations and flat, non-elevated skin surfaces. Tumors with these characteristics exhibited more than double the likelihood of belonging to higher aggressiveness categories. This insight underscores the importance of integrating specific morphological cues into computational models to refine prognostic accuracy.

Despite mounting enthusiasm for AI applications in dermatology, practical integration into routine clinical workflows has been limited to date. Polesie emphasizes that successful adoption hinges upon targeting AI development toward well-defined clinical problems where enhanced decision-making can tangibly improve patient outcomes. “Our focus has been the preoperative assessment of suspected skin cancers, an area ripe for AI’s capabilities. While our model requires further validation and optimization, its value lies in augmenting—not replacing—clinical expertise,” he asserts.

The AI employed convolutional neural networks (CNNs), a deep learning architecture adept at recognizing intricate spatial patterns within images. By training on a sizeable and diverse image repository gathered between 2015 and 2023 at the Sahlgrenska University Hospital dermatology department, the system learned to discern subtle textural and color variations indicative of tumor biology. This data-driven approach represents a leap beyond traditional diagnostic heuristics, harnessing computational power to harness cellular and tissue-level heterogeneity captured visually.

From a technical perspective, the model’s success rests on sophisticated preprocessing steps—such as normalization, segmentation, and augmentation—that enhance image quality while mitigating noise and variability inherent to clinical photography. The subsequent feature extraction phase employs filters designed to capture edges, gradients, and color contrasts associated with pathological changes. Finally, classification layers map these features onto clinically relevant aggressiveness labels, delivering probabilistic outputs that clinicians can interpret alongside their assessments.

Looking forward, the integration of this AI tool into teledermatology platforms and mobile diagnostic applications could democratize access to expert-level evaluation, particularly in resource-limited settings or remote areas. Rapid, noninvasive tumor characterization facilitated by image-based algorithms might reduce unnecessary surgeries or expedite intervention for high-risk lesions, substantially improving patient care efficiency.

Given the complexity and variability of cSCC presentation, additional studies encompassing larger, multi-center image datasets and diverse patient populations are essential. Moreover, longitudinal analyses linking AI-predicted aggressiveness with actual clinical outcomes will validate the prognostic utility of these computational assessments.

In conclusion, this research from the University of Gothenburg marks a pivotal step toward harnessing artificial intelligence as an adjunct diagnostic tool in dermatological oncology. By matching expert dermatologist performance in gauging squamous cell carcinoma aggressiveness through noninvasive imaging, the AI model demonstrates immense potential to refine surgical planning, optimize resource allocation, and ultimately improve prognosis for thousands of patients afflicted by this widespread cancer. Continued technological refinement paired with clinical validation will pave the way for AI’s meaningful integration into standard dermatological practice.

Subject of Research: People

Article Title: Assessing Differentiation in Cutaneous Squamous Cell Carcinoma: A Machine Learning Approach

News Publication Date: 1-Aug-2025

Web References:
10.1016/j.jdin.2025.07.004

References:
Journal of the American Academy of Dermatology

Image Credits: Photo: Johan Wingborg

Keywords: artificial intelligence, squamous cell carcinoma, skin cancer, dermatology, machine learning, tumor aggressiveness, convolutional neural networks, preoperative assessment, medical imaging, cancer diagnostics

Melanoma, a deadly form of skin cancer arising from melanocyte mutations, poses significant diagnostic challenges even for experienced dermatologists. Early and accurate detection is paramount, as prompt treatment dramatically improves patient prognosis, but diagnostic errors remain a common hurdle due to lesion heterogeneity and subjective visual assessment. Existing automated systems focusing solely on pixel-level pattern recognition frequently lack interpretability and contextual understanding, leading to hesitancy in clinical adoption. To address this, the research team, led by Chanda et al., conceived an AI that mimics the attention mechanisms used by dermatologists during lesion evaluation. Their approach involved collecting extensive eye-tracking data from experts as they examined dermoscopic images, thereby mapping the visual features and regions of interest prioritized during diagnosis.

The integration of eye-tracking data proved transformative, enabling the AI to learn patterns of visual attention associated with accurate clinical judgment. By aligning its focus with that of human experts, the AI could selectively analyze lesion subregions critical for melanoma differentiation, such as asymmetry, border irregularity, color variations, and structural patterns. This methodological innovation bridged the gap between conventional image classification and cognitive diagnostic processes, allowing for a layered, interpretable analysis that highlights specific lesion characteristics supporting a malignant or benign conclusion. Importantly, this mechanism empowers clinicians to interrogate and understand the AI’s diagnostic trail, promoting collaborative decision-making rather than blind reliance on algorithmic outputs.

The researchers utilized a deep convolutional neural network architecture augmented with attention modules trained on a large dermoscopic image dataset, encompassing a diverse array of pigmentary patterns and lesion types. The training phase incorporated both labeled images and corresponding eye-tracking heatmaps derived from dermatologist participants. This dual-input design enriched the model’s internal representations, enhancing its sensitivity to subtle visual cues often overlooked by conventional AI. Testing revealed that the model achieved superior diagnostic performance compared to standard AI classifiers, with a marked increase in specificity and sensitivity metrics, thereby reducing false positives and negatives that can lead to unnecessary biopsies or missed malignancies.

Crucially, explainability was embedded at each stage of the decision pipeline. The AI system generated visual maps delineating the regions it deemed most informative, mirroring the expert’s focal points. These maps were validated against independent dermatologist evaluations to confirm their diagnostic relevance. Additionally, the AI output included textual annotations referencing well-established clinical features, such as pigment network irregularity and atypical globules, offering a linguistically accessible rationale for each classification. This dual modality—visual and textual explanation—addresses the complex interpretative needs of dermatologists, whose expertise blends perceptual acuity with nuanced clinical knowledge.

Beyond technical advancements, the study’s implications extend to clinical practice and patient outcomes. By demystifying the AI’s decision-making process, dermatologists can more confidently integrate this tool into routine screening workflows, using it as a second opinion or real-time assistant, especially in ambiguous cases. This could alleviate diagnostic workloads, streamline referrals, and optimize resource allocation within dermatology clinics. Moreover, patients stand to benefit from earlier detection, enhanced diagnostic precision, and personalized treatment plans informed by transparent, interpretable AI insights.

The use of eye-tracking as a foundational element is notable not only for its innovation but also for its interdisciplinary nature, uniting cognitive psychology, computer vision, and clinical medicine. Eye-tracking captures implicit expert knowledge that is difficult to articulate yet critical in visual diagnosis, thus encoding a layer of tacit expertise into machine learning models. This paradigm shift towards embedding cognitive signatures into AI promises to enhance the interpretability and clinical relevance of diagnostic systems across medical specialties where visual assessment dominates.

While the results are promising, the authors acknowledge challenges ahead. Scaling the model for diverse populations with varying skin types and lesion presentations will require expansive, representative datasets. Additionally, regulatory frameworks governing medical AI must evolve to account for explainable systems, ensuring safety and efficacy while fostering innovation. Integrating this technology within existing electronic health records and teledermatology platforms also presents technical and logistical complexities that necessitate collaborative stakeholder engagement.

Future research directions include refining the granularity of attention mapping, enabling the AI to dynamically adjust its focus based on lesion context and patient history. Combining multimodal data inputs such as genetic markers or patient demographics could further enhance predictive accuracy. Moreover, longitudinal studies assessing real-world diagnostic improvements, patient outcomes, and cost-effectiveness will be crucial to validate the clinical utility of this dermatologist-like AI system.

The transformative potential of explainable AI in dermatology exemplifies a broader trend towards human-centered machine learning in medicine. By fostering transparency and trust, these systems can augment rather than replace clinical expertise, empowering physicians with enhanced diagnostic tools. The fusion of cognitive science and artificial intelligence heralds a new era in healthcare innovation, where machines learn from and collaborate with human professionals to improve patient care in profound ways.

In conclusion, the study by Chanda, Haggenmueller, Bucher, and colleagues marks a significant milestone in the evolution of medical AI, demonstrating how embedding expert cognitive processes and explainability can dramatically enhance melanoma diagnosis accuracy. Beyond melanoma, this approach offers a template for deploying explainable AI in other visual diagnostic domains, promising safer, more reliable, and clinically acceptable AI-assisted medicine. As research progresses, such interdisciplinary innovations may fundamentally reshape diagnostic paradigms, paving the way for AI systems that truly think—and explain—like doctors.

Subject of Research: Explainable Artificial Intelligence for melanoma diagnosis using eye-tracking data to emulate dermatologist visual attention and improve diagnostic accuracy.

Article Title: Dermatologist-like explainable AI enhances melanoma diagnosis accuracy: eye-tracking study.

Article References:
Chanda, T., Haggenmueller, S., Bucher, TC. et al. Dermatologist-like explainable AI enhances melanoma diagnosis accuracy: eye-tracking study. Nat Commun 16, 4739 (2025). https://doi.org/10.1038/s41467-025-59532-5

Image Credits: AI Generated